

Global event on enhancing the sustainability of investment for vaccine manufacturing in Africa. 27-29 June 2023

United Nations Conference Centre, UNECA, Addis Ababa, Ethiopia

Background

The event is co-convened by the United Nations Conference on Trade and Development (UNCTAD), the African Vaccine Manufacturers Initiative (AVMI) and the Africa Centres for Disease Control and Prevention (Africa CDC).

Following the COVID-19 pandemic, African countries and development partners have prioritised investment into vaccines manufacturing capacity with a view to overcome health inequities. The Partnership for African Vaccine Manufacturing (PAVM), under Africa CDC was launched in 2021 and its Framework for Action in 2022. PAVM targets a call by the African Union heads of State and Government for the local production of 60% of the vaccine the region requires by 2040.

Objectives

Around 30 investment initiatives for vaccines manufacturing in Africa have been announced since COVID-19. The key question that the event is intended to address is how to develop sustainable investment in vaccine manufacturing that will mitigate the risks and ensure financial sustainability. For this purpose, the event will:

- 1. Outline the progress made on investment in vaccine manufacturing in Africa, while creating transparency on the current financing gap, as well as the pain points experienced by investment projects to date.
- 2. Provide a platform to facilitate business to business linkages and matchmaking between investors, manufacturers, and financial providers.
- 3. Identify potential solutions to enhance sustainability of investment.

The event will also facilitate initial exchange on the opportunities for investment in biopharmaceuticals that are critical to making vaccines investment sustainable.

Who is attending?

- African pharmaceutical firms interested in the production of vaccines and biopharmaceuticals and existing manufacturers interested to expand their production.
- Investors and funders interested to invest into the production of vaccines and other biopharmaceutical products in Africa.
- Multinational enterprises (MNEs), contract manufacturers, biopharmaceutical technology developers and facilitators interested to invest or form partnerships for investment in Africa.
- Development partners and regional facilitators.

The event organizers will convey and follow up the outcomes of the event within intergovernmental processes, global partnerships and business to business networks that are contributing to building vaccines production capacity in Africa.

The financial support for the organization of the event is provided by the Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH, commissioned by the German Federal Ministry for Economic Cooperation and Development, which is implementing several support programmes with the co-conveners of the event and other partners across Africa for vaccines production.

The event will be conducted in English.

PROGRAMME					
DAY 1	27 June 2023				
Time	Topic and moderator	Speakers/facilitators			
13:30 - 14:00	Registration	All Participants			
14:00 – 14:15	Welcome and introduction of the event	Event co-conveners.			
14:15 – 14:45	Opening statement <i>Chair: H.E. Amb. Ces-</i> <i>souma Minata Samate,</i> <i>Commissioner for Health,</i> <i>Humanitarian Affairs and</i> <i>Social Development</i> <i>(DHHS), AUC</i>	 H.E. Amb. Cessouma Minata Samate, Commissioner for Health, Humanitarian Affairs and Social Development (DHHS), AUC Dirk Meyer, Head, Global Health; Economy; Trade; Rural Development Department, Fed- eral Ministry for Economic Cooperation and Development (BMZ) Mr Martin Seychell, Deputy Director-General DG INTPA, European Commission 			
14:45 – 15:00	Keynote address Chair: H.E. Amb. Ces- souma Minata Samate, Commissioner for Health, Humanitarian Affairs and Social Development (DHHS), AUC	Dr. Lia Tadese, Minister of Health, FDRE			
Ses	Session 1: Supporting the agenda for vaccine production in Africa.				
15:00 – 16:00	PAVM: Reflections on the state of play and progress,	Akhona Tshangela, Programme Coordinator PAVM, Africa CDC			
	Facilitated by Patrick Tippoo, AVMI	Akhona Tshangela, Africa CDC Mr Martin Seychell, Deputy Director-General DG INTPA, European Commission Team Europe Partners			
16:00 - 16:30	Heal	th Break and Group photo			
Session 2: Pain points and success factors of investment for vaccines manufacturing.The session will include reflections of the global industry, the assessment of the pain points and the relevant success factors of investment initiatives for vaccines manufacturing in Africa.16:30 – 18:30Reflections on the state of play and progressGreg Perry, Assistant Director General, IFPMA					
	Trend on investment initiatives	Philip Dorrell, CHAI, Program Manager, Vaccine Markets.			
	Reflections on investment pain points and success factors	Alastair West, Consultant and Ermias Biadgleng, Legal Expert, Division on Investment and Enterprise, UNCTAD			
	Perspectives from the African vaccine industry	Patrick Tippoo, Executive Director, AVMI			
18:30 – 21:00	Q&A Networking reception				

DAY 2

28 June 2023

Session 3: Opportunities for investment and partnerships on vaccines and biopharmaceuticals.

During this session, international and African firms, and technology facilitators will present what they intend to bring and what they seek, including joint venture, finance, and other partnerships. Through a series of short and focused presentations businesses can identify and narrow down their potential partners.

The representative of each company will be invited to address the following three questions under a roundtable discussion.

- a) What is the current portfolio, focus and capacity of the company?
- b) What are its plans for investment, and/or what it can provide to other partners?
- c) What it seeks for the realization of its investment initiatives from other partners (businesses, finance, and technology providers)?

10:00 - 10:40	Round table 1: African companies and partners		
	1. Dr Simon Agwale, CEO, Innovative Biotech Ltd, Nigeria		
	2. Farrah Losper, Chief Commercial Officer, Biovac, South Africa.		
	3. Mr. David Klutse, Deputy CEO, Atlantic life sciences, Ghana		
	4. Dr. Rania Mohsen Head of Technical affairs, VACSERA		
10:40 - 11:20	Round table 2: African companies and partners		
	1. Dr. Nibal Dahaba, General Manager, Gennecs, Egypt		
	2. Dr Stavros Nicolaou, Group Senior Executive: Strategic Trade Development,		
	Aspen Pharmacare		
	3. Amenya Wokoma, Managing Director/CEO, Nigeria Integrated		
	Biopharmaceuticals Industries Consortium (NIBI)		
	4. Prof William Ampofo, CEO, National Vaccine Institute, Ghana		
11:20 – 11:40	Health break		
11:40 - 13:00	Round table 3a: International partners: vaccine and technology companies		
	Co-moderator: Greg Perry, Assistant Director General, IFPMA		
	1. Adélaïde Cejudo, Public Affairs Lead, Africa and International Public Funded Mar-		
	ket and Esin Ozge Kavustu, Head of International Funded Public Market, Sanofi		
	Vaccines		
	Sarah Reynolds Regional Strategy Manager - Africa at Merck Life Science		
	3. Barend Jansen van Vuuren, Emerging Market Manager, Global Health Equity		
	Business, Thermo Fisher		
	4. Ariane McCabe, Lead Global Health Policy & Advocacy and Geneva Advocacy,		
	GlaxoSmithKline PLC		
	5. Jin S, Park, Vice President, Global Public Health, SK bioscience		
	6. Rachel Park, Director, Eubiologics		
13:00 – 14:00	Networking lunch (buffet lunch)		
14:00 - 14:40	Round table 3b: International partners: facilitators for local production		
	7. Hala Audi, Chief Executive Officer, UNIZIMA, Benoit Gregoire, BD Manager and		
	Sr. Tech Transfer Expert, UNIZIMA, Johnny Vlaminck, Business Development		
	Manager and licensing expert (Univercelles Group)		

	8. Mr Holm Keller, Executive Chairman, KENUP Foundation		
	9. Junhee (Jaybrant) Lee, Business Development Manager, International Vaccine		
	Institute (IVI), Korea 10. Prof Petro Terblanche, Managing Director, Afrigen Biologics and Vaccines Prof		
	Petro Terblanche, Managing Director, Afrigen Biologics and Vaccines		
14:40 - 15:30	Round table 4: African companies and partners		
	 Mina Adel, Business Development and Regulatory Affairs Manager, BioGeneric Pharma S.A.E (BGP), Egypt 		
	2. Dr. Dereje Nigussie, Director, Vaccines, Medical devices Diagnostics Directorate,		
	Armauer Hansen Research Institute (AHRI), Ethiopia		
	3. Matthias Magoola CEO, DEI BioPharma, Uganda		
	4. Dr Amadou Sall, Director General, Institut Pasteur de Dakar, Senegal		
	5. Dr Benazzouz Safouane, Institut Pasteur d'Algérie		
15:30 – 15:50	Health Break		
15:50 – 16:50	Round table 5: African companies and partners		
	1. Prof. Elijah Songok, Director General, Kenya Medical Research Institute (KEMRI)		
	2. Kofi Nsiah-Poku, DEK Vaccines Ltd, Ghana.		
	3. Cecilia Wanjala, Kenya BioVax Institute		
	 Mohammed Umar, CEO, Pharmonova, Zambia Younes Hillali, General Manager, MARBIO, Morocco 		
	6. Dr Nizar Laabid, Production Manager, Institut Pasteur de Tunis		
Se	ession 4: Investment finance for vaccines manufacturing in Africa.		
	nce providers and private equity funds will have the opportunity to present their financial		
	d what they expect from investors. Project preparation and the resource mobilization to		
	ccine industry ecosystem enablers will also be discussed.		
16:50 – 17:30	1. Ghada Abuzaid, Principal Industrial (& Pharmaceutical) Program Coordinator,		
	AfDB, and Nazeem Mohamed, Consultant, AfDB		
	 Christian Ndikumagenge, Manager, Export Development, Afrexim Bank Arnaud Bonnet, Managing Director, Lion's Head 		
17:30 - 17:50	Reflections from development partner, Axel Klaphake, GIZ		
17:50 – 18:30	Discussion based on questions from manufacturers		
18:30 – 20:15: Networking Reception			

DAY 3	29 .	June 2023			
Session 5: Panel Discussion on market shaping and off-take mechanisms.					
Co-Moderator, Stephen Karingi, Director, Regional Integration and Trade Division, UNECA					
09:00 - 09:20	Overall market shaping strategy for Africa, Prof. Padmasree Gehl Sampath				
09:20 - 10:20	Shaping regional markets and off-take mechanisms: What concrete steps are taken by global and regional initiatives?				
	 Dorcas Noertoft, Chief of Dr. Frauke Uekermann, C Initiative (CHAI) 	dviser, Development Finance, GAVI Procurement Services, UNICEF CHAI, Director, Vaccine Markets, Clinton Health Access ger, Trade Finance (Afrexim Bank- African Vaccine initiative).			
10:20 – 10:40	 Joshua Bright Eleblu, Hea Directorate, Ministry of He Dr. Maimuna Hamisu, Na NPCDA, Nigeria. Dr. Hisham Stait, Vice Ch 	s of government procurement agencies ad, Logistics Unit, Procurement and Supply Chain ealth, Ghana tional Primary Health Care Development Agency nairman of the Board of Directors, Egyptian Authority for al Supply and The Management of Medial Technology.			
10:40 - 11:20	Open Discussion				
11:20- 11:40	Health Break				
11:40 - 12:00	Shaping regional market with trad	e and investment policy: AfCFTA & UNCTAD			
Breakout discussions on how to enhance the sustainability of investment for vaccine manufacturing in Africa.					
12:00 - 12:10	Introduction to breakout sessions,	, UNCTAD and AVMI			
Two breakout se	Two breakout sessions for a focused discussion on business models, challenges, and opportunities.				
Workshop 1	: Drug Product manufacturing	Facilitated by UNIZIMA and AVMI.			
Workshop 2	: Drug Substance manufacturi	ng. Facilitated by AVMI and UNCTAD			
		technology providers, development partners and should tions of opportunities and challenges.			
12:10 – 12:45 Parallel presentations in breakout rooms					
Workshop 1	: Drug Product manufacturing.	Workshop 2: Drug Substance manufacturing.			

 Presentation of business model for fill and finish investment Hala Audi, CEO, UNIZIMA Q&A and open discussion by all participants 		 Presentation of cost/business model for drug substance manufacturing Stefanie Perrella, Zachary Held, Kroll; & Rick Stock, BDO (consultants for Bill & Melinda Gates Foundation) Q&A and open discussion by all participants 		
12:45 – 13:45	Group lunch and continuation of g	roup discussion		
13:45 – 15:30	Group discussions and preparation	on of the summary of outcomes		
Workshop 1: Drug Product manufacturing.		Workshop 2: Drug Substance manufacturing.		
Questions to be	answered:	Questions to be answered:		
 What are the opportunities and challenges for fill and finish investment? Who and what can contribute to realize the opportunities and overcome the challenges? What is the next step for partners? 		 What are the opportunities and challenges for drug substance manufacturing with (a) traditional (b) modern technologies in Africa? Who and what can contribute to realize the opportunities and overcome the challenges? What is the next step for partners? 		
15:30 – 16:00	Group Health Break			
Plenary discussion on the outcomes of the breakout discussion: Plenary session				
16:00 – 17:00	Presentation of outcomes of the discussions (20 minutes for each group) Questions and comments from other groups (15 minutes each)			
17:30 – 17:45	Event evaluation and suggestions for further action (UNCTAD, AVMI and Africa CDC)			
17:45 – 18:15	Closing ceremony.			



Please contact Ermias Biadgleng, at ermias.biadgleng@un.org for further information on the programme.